New data from a large, international registry showed balloon-assisted anterior mitral leaflet modification (BATMAN) was safe, ...

Right ventricular strain and right ventricular outflow tract velocity time integral are associated with mortality in ...

LVOT-G measures the difference in pressure between the heart’s left ventricle and aorta. This reduction in pressure was achieved without a meaningful change in left ventricular ejection fraction ...

The review extension was needed as the FDA required time to review Cytokinetics’ proposed Risk Evaluation and Mitigation Strategy (REMS).

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

Our Bureau, Chennai Wednesday, April 23, 2025, 13:40 Hrs [IST] ...

EDG-7500 is a novel oral, selective, cardiac sarcomere modulator ... HCM demonstrated robust reductions in left ventricular outflow tract gradient (LVOT-G) without meaningful changes in left ...

Citing data from its Phase 2 CIRRUS trial, EWTX said that in patients with the obstructive form of HCM, EDG-7500 led to “rapid and clinically meaningful” declines in left ventricular outflow ...

Left ventricular outflow tract; NSVT: Nonsustained ventricular tachycardia; SCD: Sudden cardiac death; VF: Ventricular fibrillation; VT: Ventricular tachycardia. 1 Division of Cardiovascular ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.